



WHAT IS CLAIMED IS:


1. A bicyclic aromatic compound having the structural formula (I):




in which  $\text{R}_1$  is (i) the radical  $-\text{CH}_3$ , (ii) a radical  $-\text{CH}_2\text{OR}_2$ , or (iii) a radical  $-\text{CO}-\text{R}_3$ , wherein  $\text{R}_2$  and  $\text{R}_3$  are as defined below;  $\text{Ar}_1$  is a radical selected from among those of the following formulae (a)-(c):



(a)




(b)




(c)


wherein  $\text{R}_4$ ,  $\text{R}_5$ ,  $\text{R}_6$ ,  $\text{R}_7$ ,  $\text{R}_8$ ,  $\text{R}_9$ ,  $\text{R}_{10}$  and  $\text{R}_{11}$  are as defined below;  $\text{Ar}_2$  is a radical selected from among those of the following formulae (d)-(h):



wherein  $R_{12}$  and  $R_{13}$  are as defined below; X is a radical selected from among those of the following formulae (i) - (l):



wherein  $R_{14}$ ,  $R_{15}$  and Y are as defined below;  $R_2$  is a hydrogen atom, a lower alkyl radical or a radical -CO- $R_{16}$ , wherein  $R_{16}$  is as defined below;  $R_3$  is a hydrogen atom, a lower alkyl radical, a radical of the formula:



wherein R' and R" are as defined below, or a radical  
-OR<sub>17</sub>, wherein R<sub>17</sub> is as defined below; R<sub>4</sub> is a hydrogen  
atom, a polyether radical, a lower alkyl radical, or a  
radical -OR<sub>18</sub>, wherein R<sub>18</sub> is as defined below; R<sub>5</sub> is a  
5 hydrogen atom, a lower alkyl radical, a polyether  
radical, or a radical -OR<sub>19</sub>, wherein R<sub>19</sub> is as defined  
below; R<sub>6</sub> is a tert-butyl radical; R<sub>7</sub> is a lower alkyl  
radical, a polyether radical, or a radical -OR<sub>20</sub>,  
wherein R<sub>20</sub> is as defined below, with the proviso that R<sub>6</sub>  
10 and R<sub>7</sub> may together form, with the carbon atoms from  
which they depend, a 6-membered ring optionally  
substituted with at least one methyl group and/or  
optionally interrupted by an oxygen or sulfur atom; R<sub>8</sub>  
is a tert-butyl, adamantyl, aryl or aralkyl radical; R<sub>9</sub>  
15 and R<sub>10</sub> together form, with the carbon atoms from which  
they depend, a 5- or 6-membered ring optionally  
substituted with at least one methyl group and/or  
optionally interrupted by an oxygen or sulfur atom; R<sub>11</sub>  
is a hydrogen atom, a lower alkyl radical having from 1  
20 to 9 carbon atoms, a hydroxyl radical, an alkoxy  
radical, a polyether radical or a radical -OR<sub>21</sub>, wherein  
R<sub>21</sub> is as defined below; R<sub>12</sub> is a hydrogen atom, a  
hydroxyl radical, an alkoxy radical, a polyether radical  
or a radical -OR<sub>22</sub>, wherein R<sub>22</sub> is as defined below; R<sub>13</sub>  
25 is a hydrogen atom, a lower alkyl radical, or a radical  
-COR<sub>23</sub>, wherein R<sub>23</sub> is as defined below; R<sub>14</sub> and R<sub>15</sub>,  
which may be identical or different, are each a hydrogen

atom, or a lower alkyl radical; Y is an oxygen atom or a CH<sub>2</sub> radical; R<sub>16</sub> is a lower alkyl radical; R<sub>17</sub> is a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono-  
5 or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical or a sugar residue; R' and R", which may be identical or different, are each a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an  
10 amino acid residue, with the proviso that R' and R" may together form, with the nitrogen atom from which they depend, a nitrogenous heterocycle; R<sub>18</sub>, R<sub>19</sub> and R<sub>20</sub>, which may be identical or different, are each a hydrogen atom, a lower alkyl radical, an alkenyl radical, a mono-  
15 or polyhydroxyalkyl radical, an aryl radical, an optionally substituted aralkyl radical or a radical -(CH<sub>2</sub>)<sub>n</sub>-R<sub>24</sub>, wherein n and R<sub>24</sub> are as defined below; R<sub>21</sub> and R<sub>22</sub>, which may be identical or different, are each an alkenyl radical, a mono- or polyhydroxyalkyl radical,  
20 an aryl radical, an optionally substituted aralkyl radical, or a radical -(CH<sub>2</sub>)<sub>n</sub>-R<sub>24</sub>, wherein n and R<sub>24</sub> are as defined below; R<sub>23</sub> is a lower alkyl radical; R<sub>24</sub> is a heterocycle, a monohydroxyalkyl radical, a thiol radical optionally substituted with a lower alkyl radical, an  
25 amino radical optionally substituted with at least one lower alkyl radical, a radical -COOR<sub>25</sub>, or a radical -CON(R<sub>26</sub>)R<sub>27</sub>, wherein R<sub>25</sub>, R<sub>26</sub> and R<sub>27</sub> are as defined below; R<sub>25</sub> is a hydrogen atom or a lower alkyl radical;

$R_{26}$  and  $R_{27}$ , which may be identical or different, are each a hydrogen atom, a lower alkyl radical, or an optionally substituted aryl radical, with the proviso that  $R_{26}$  and  $R_{27}$  may together form, with the nitrogen atom from which they depend, a nitrogenous heterocycle;  $n$  is an integer such that  $2 \leq n \leq 9$ ; with the further provisos that, when  $Ar_1$  is the radical of formula (c) and  $X$  is a radical of formulae (i) or (j), then  $R_{11}$  is a radical  $-OR_{21}$  or a polyether radical, or when  $Ar_2$  is the radical of formula (d), then  $R_{12}$  is a radical  $-OR_{22}$  or a polyether radical, and the compounds of formula (I) do not include those wherein  $R_{11}$  is a methoxymethoxy radical in an ortho position relative to the substituent  $Ar_2$  when  $Ar_1$  is the radical of formula (c),  $X$  is the radical of formula (i),  $R_{12}$  is hydrogen and  $R_1$  is a radical  $-COR_3$  wherein  $R_3$  is a radical  $-OR_{17}$  and  $R_{17}$  is a hydrogen atom, and those wherein  $R_{12}$  is a methoxymethoxy radical in an ortho- or para-position relative to the substituent  $Ar_1$  when  $Ar_1$  is the radical of formula (c),  $X$  is the radical of formula (i),  $R_{11}$  is a methyl radical in an ortho-position relative to  $Ar_2$ , and  $R_1$  is a radical  $-COR_3$  wherein  $R_3$  is a radical  $-OR_{17}$  and  $R_{17}$  is a hydrogen atom; and the pharmaceutically/cosmetically acceptable optical and geometric isomers and salts thereof.

2. A bicyclic aromatic compound as defined by Claim 1, wherein formula (I), Ar<sub>1</sub> is a radical having the formula (a).

3. A bicyclic aromatic compound as defined by  
5 Claim 1, wherein formula (I), Ar<sub>1</sub> is a radical having the formula (b).

4. A bicyclic aromatic compound as defined by Claim 1, wherein formula (I), Ar<sub>1</sub> is a radical having the formula (c).

10 5. A bicyclic aromatic compound as defined by any of Claims 2-4, wherein formula (I), Ar<sub>2</sub> is a radical having the formula (d).

6. A bicyclic aromatic compound as defined by any of Claims 2-4, wherein formula (I), Ar<sub>2</sub> is a radical  
15 having the formula (e).

7. A bicyclic aromatic compound as defined by any of Claims 2-4, wherein formula (I), Ar<sub>2</sub> is a radical having the formula (f).

8. A bicyclic aromatic compound as defined by any  
20 of Claims 2-4, wherein formula (I), Ar<sub>2</sub> is a radical having the formula (g).

9. A bicyclic aromatic compound as defined by any of Claims 2-4, wherein formula (I),  $Ar_2$  is a radical having the formula (h).

10. A bicyclic aromatic compound as defined by  
5 Claim 5, wherein formula (I), X is a radical (i).

11. A bicyclic aromatic compound as defined by Claim 6, wherein formula (I), X is a radical (j).

12. A bicyclic aromatic compound as defined by Claim 7, wherein formula (I), X is a radical (k).

10 13. A bicyclic aromatic compound as defined by Claim 8, wherein formula (I), X is a radical (l).

14. A bicyclic aromatic compound as defined by Claim 1, comprising a pharmaceutically/cosmetically acceptable salt thereof.

15 15. A bicyclic aromatic compound as defined by Claim 1, wherein formula (I),  $R_1$  is a radical  $-CO-R_3$ ;  $Ar_1$  is a radical of formulae (d) or (e);  $R_{11}$  is a radical  $-O-R_{21}$ ; and  $R_7$  is a radical  $-O-R_{20}$ .

16. A bicyclic aromatic compound as defined by  
20 Claim 1, selected from among

- 3-(3',5'-di-tert-butyl-2'-methoxy-3-biphenyl)acrylic  
acid; 3-(2'-benzyloxy-3',5'-di-tert-butyl-6-hydroxy-3-  
biphenyl)acrylic acid; 3-(3',5'-di-tert-butyl-6-  
hydroxy-2'-pentyloxy-3-biphenyl)acrylic acid; 3-  
5 (3',5'-di-tert-butyl-6-hydroxy-2'-methoxy-3-  
biphenyl)acrylic acid; 3-[3-(3-benzyloxy-5,5,8,8-  
tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-  
methoxymethoxyphenyl]acrylic acid; 3-[3-(3-benzyloxy-  
5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-  
hydroxyphenyl]acrylic acid; [4-methoxymethoxy-3-  
10 (3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-  
naphthyl)phenyl]propynoic acid; 3-[3-(3-propyloxy-  
5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-  
methoxymethoxyphenyl]acrylic acid; 3-[3-(3-pentyloxy-  
15 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-  
methoxymethoxyphenyl]acrylic acid; 3-(5'-adamantan-1-yl-  
4'-methoxy-2'-methyl-3-biphenyl)acrylic acid; 3-(5'-  
adamantan-1-yl-6-hydroxy-4'-methoxy-2'-methyl-3-  
biphenyl)acrylic acid; 3-(5'-adamantan-1-yl-4'-  
20 methoxy-6-methoxymethoxy-2'-methyl-3-biphenyl)acrylic  
acid; 3-{4-methoxy-3-[3-(3-methoxybenzyloxy)-5,5,8,8-  
tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic  
acid; 3-{4-methoxy-3-[3-(4-methoxybenzyloxy)-5,5,8,8-  
25 5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic  
acid; 3-{3-[3-(6-hydroxyhexyloxy)-5,5,8,8-tetramethyl-  
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic  
acid; 3-{3-[3-(7-hydroxyheptyloxy)-5,5,8,8-tetramethyl-  
5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic



acid; 3-{3-[3-(5-hydroxypentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{3-[3-(3-hydroxypropyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-[3-(1-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrylic acid; 3-(3'-adamantan-1-yl-4'-hydroxy-3-biphenyl)acrylic acid; 5-[4-methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-[4-methoxymethoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-[4-hydroxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 3-{3-[3-(5-tert-butoxycarbonylpentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{3-[3-(7-tert-butoxycarbonylheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{3-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{3-[3-(5-carboxypentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{3-[3-(5-carbamoylpentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{3-[3-(7-carbamoylheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]-4-methoxyphenyl}acrylic acid; 3-{4-methoxy-3-[5,5,8,8-tetramethyl-3-(2-morpholin-4-ylethoxy)-5,6,7,8-

tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-methoxy-  
3-[5,5,8,8-tetramethyl-3-(2-piperidin-1-ylethoxy) -  
5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-  
methoxy-3-[3-(2-methoxymethoxybenzyloxy) -5,5,8,8-  
5 tetramethyl-5,6,7,8-tetrahydro-2-naphthyl]phenyl}acrylic  
acid; 3-{4-methoxy-3-[3-(3-methoxymethoxybenzyloxy) -  
5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-  
naphthyl]phenyl}acrylic acid; 3-{4-methoxy-3-[3-(4-  
methoxymethoxybenzyloxy) -5,5,8,8-tetramethyl-5,6,7,8-  
10 tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-methoxy-  
3-[3-(3-hydroxybenzyloxy) -5,5,8,8-tetramethyl-5,6,7,8-  
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-[4-fluoro-  
3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-  
naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-3-[3-(3-  
15 methoxybenzyloxy) -5,5,8,8-tetramethyl-5,6,7,8-  
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-  
3-[3-(4-methoxybenzyloxy) -5,5,8,8-tetramethyl-5,6,7,8-  
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-  
3-[3-(4-fluorobenzyloxy) -5,5,8,8-tetramethyl-5,6,7,8-  
20 tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-{4-hydroxy-  
3-[3-(4-chlorobenzyloxy) -5,5,8,8-tetramethyl-5,6,7,8-  
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-[4-hydroxy-  
3-(3-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-  
tetrahydro-2-naphthyl]phenyl}acrylic acid; 3-(3',5'-di-  
25 tert-butyl-6-hydroxy-2'-propyloxy-3-biphenyl)acrylic  
acid; 3-(3',5'-di-tert-butyl-6-hydroxy-2'-butyloxy-3-  
biphenyl)acrylic acid; 3-(2'-butoxy-3',5'-di-tert-  
butyl-6-methoxy-3-biphenyl)acrylic acid; 3-(3'5'-di-

tert-butyl-6-methoxy-2'-propoxy-3-biphenyl) acrylic acid; 3-[4-hydroxy-3-(5,5,8,8-tetramethyl-4-propoxy-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrylic acid; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylic acid; ethyl 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylate; 3-methyl-5-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]penta-2,4-dienoic acid; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]prop-2-en-1-ol; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]propenal; N-ethyl 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylamide; 3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]-1-morpholin-4-yl-propenone; N-(4-hydroxyphenyl)-3-[3-(3-benzyloxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxyphenyl]acrylamide; 5-(5'-adamantan-1-yl-4'-methoxy-2'-methyl-3-biphenyl)-3-methylpenta-2,4-dienoic acid; 5-[4-methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 5-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]-3-methylpenta-2,4-dienoic acid; 4-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]penta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-2'-methoxy-3-biphenyl)-3-

methylopenta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-2'-propoxy-3-biphenyl)-3-methylopenta-2,4-dienoic acid; 5-(2'-butoxy-3',5'-di-tert-butyl-3-biphenyl)-3-methylopenta-2,4-dienoic acid; 5-(2'-butoxy-3',5'-di-tert-butyl-6-hydroxy-3-biphenyl)-3-methylopenta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-6-hydroxy-2'-propoxy-3-biphenyl)-3-methylopenta-2,4-dienoic acid; 5-(3',5'-di-tert-butyl-6-hydroxy-2'-methoxy-3-biphenyl)-3-methylopenta-2,4-dienoic acid.

10           17. A bicyclic aromatic compound as defined by Claim 1, having the formula (I) and containing at least one lower alkyl radical substituent selected from among methyl, ethyl, isopropyl, butyl, tert-butyl and hexyl radicals.

15           18. A bicyclic aromatic compound as defined by Claim 1, having the formula (I) and containing at least one monohydroxyalkyl radical substituent selected from among 2-hydroxyethyl, 2-hydroxypropyl and 3-hydroxypropyl radicals.

20           19. A bicyclic aromatic compound as defined by Claim 1, having the formula (I) and containing at least one polyhydroxyalkyl radical substituent selected from among 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl, 2,3,4,5-tetrahydroxypentyl and pentaerythritol radicals.

20. A bicyclic aromatic compound as defined by  
Claim 1, having the formula (I) and containing at least  
one aryl radical substituent selected from among phenyl  
radicals optionally substituted by at least one halogen  
5 atom, or at least one lower alkyl, alkoxy, polyether,  
optionally protected amino, hydroxyl or nitro group.

21. A bicyclic aromatic compound as defined by  
Claim 1, having the formula (I) and containing at least  
one aralkyl radical substituent selected from among  
10 benzyl and phenethyl radicals optionally substituted by  
at least one halogen atom, or at least one lower alkyl,  
alkoxy, polyether, optionally protected amino, hydroxyl  
or nitro group.

22. A bicyclic aromatic compound as defined by  
15 Claim 1, having the formula (I) and containing at least  
one sugar residue substituent selected from among those  
of glucose, galactose, mannose and glucuronic acid.

23. A bicyclic aromatic compound as defined by  
Claim 1, having the formula (I) and containing at least  
20 one amino acid residue substituent selected from among  
those of lysine, glycine and aspartic acid.

24. A bicyclic aromatic compound as defined by  
Claim 1, having the formula (I) and containing at least  
one heterocyclic radical substituent selected from among

piperidino, morpholino, pyrrolidino and piperazino radicals which are optionally substituted by a C<sub>1</sub>-C<sub>6</sub> alkyl radical or a mono- or polyhydroxyalkyl radical.

25. A bicyclic aromatic compound as defined by  
5 Claim 1, having the formula (I) and containing at least one alkenyl radical substituent having from 2 to 5 carbon atoms and one or more sites of ethylenic unsaturation.

26. A bicyclic aromatic compound as defined by  
10 Claim 1, having the formula (I) and containing at least one polyether radical substituent selected from among methoxymethyl ether, methoxyethoxymethyl ether and methylthiomethyl ether radicals.

27. A pharmaceutical composition of matter,  
15 comprising a therapeutically effective amount of a bicyclic aromatic compound as defined by Claim 1, or pharmaceutically acceptable salt or isomer thereof, and a pharmaceutically acceptable carrier, diluent or vehicle therefor.

20 28. The pharmaceutical composition as defined by Claim 27, further comprising a retinoid compound, a D vitamin or derivative thereof, a corticosteroid, an anti-free radical agent, an antioxidant, an  $\alpha$ -hydroxy or

$\alpha$ -keto acid or derivative thereof, an ion channel blocker, or combination thereof.

29. The pharmaceutical composition as defined by Claim 27, comprising a tablet, a capsule, a syrup, a  
5 suspension, an elixir, a solution, a powder, granules, an emulsion, microspheres, nanospheres, lipid vesicles, polymeric vesicles, or an injectable.

30. The pharmaceutical composition as defined by Claim 27, comprising an ointment, a cream, a milk, a  
10 pommade, a salve, an impregnated pad, a gel, a spray, or a lotion.

31. The pharmaceutical composition as defined by Claim 27, adopted for topical administration.

32. The pharmaceutical composition as defined by  
15 Claim 27, adopted for systemic administration.

33. The pharmaceutical composition as defined by Claim 27, comprising from 0.001% to 5% by weight of said bicyclic aromatic compound, or salt or isomer thereof.

34. A regime/regimen for treating a keratinization  
20 disorder in a mammalian organism in need of such treatment, comprising administering to such organism a

therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

35. A regime/regimen for treating a dermatological disorder in a mammalian organism in need of such  
5 treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

36. A regime/regimen for treating an  
ophthalmological disorder in a mammalian organism in  
10 need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined in Claim 27.

37. A regime/regimen for treating skin aging in a mammalian organism in need of such treatment, comprising  
15 administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined in Claim 27.

38. A regime/regimen for treating epidermal and/or dermal atrophy in a mammalian organism in need of such  
20 treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.



39. A regime/regimen for treating a cicatrization disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined in Claim 27.

40. A regime/regimen for treating a sebaceous function disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

41. A regime/regimen for treating a cancerous or precancerous disease state in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

42. A regime/regimen for treating inflammation in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

43. A regime/regimen for treating a viral infection in a mammalian organism in need of such treatment, comprising administering to such organism a

therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

44. A regime/regimen for treating or preventing alopecia in a mammalian organism in need of such  
5 treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

45. A regime/regimen for treating a cardiovascular disorder in a mammalian organism in need of such  
10 treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

46. A regime/regimen for treating an immune deficiency in a mammalian organism in need of such  
15 treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

47. A regime/regimen for treating a dermatological, rheumatic, respiratory, cardiovascular  
20 or ophthalmologic disorder in a mammalian organism in need of such treatment, comprising administering to such organism a therapeutically effective amount of the pharmaceutical composition as defined by Claim 27.

48. A regime/regimen as defined by Claim 47, comprising administering to such organism a daily dose of said bicyclic aromatic compound of about 0.01 mg/kg to 100 mg/kg of body weight thereof.

5           49. A cosmetic composition of matter, comprising a cosmetically effective amount of a bicyclic aromatic compound as defined by Claim 1, or cosmetically acceptable salt or isomer thereof, and a cosmetically acceptable carrier, diluent or vehicle therefor.

10           50. The cosmetic composition as defined by Claim 47, comprising a cream, a milk, a lotion, a gel, microspheres, nanospheres, lipid vesicles, polymeric vesicles, a soap, or a shampoo.

15           51. The cosmetic composition as defined by Claim 49, comprising from 0.001% to 3% by weight or said bicyclic aromatic compound, or salt or isomer thereof.

20           52. The cosmetic composition as defined by Claim 49, further comprising a retinoid compound, a D vitamin or derivative thereof, a corticosteroid, an anti-free radical agent, an antioxidant, an  $\alpha$ -hydroxy, or  $\alpha$ -keto acid or derivative thereof, an ion channel blocker, or combination thereof.

53. A regime/regimen for treating a skin or hair disorder on a mammalian organism in need of such treatment, comprising administering to such organism a cosmetically/therapeutically effective amount of the cosmetic composition as defined by Claim 49.

54. The pharmaceutical composition as defined by Claim 27, further comprising a wetting agent, a depigmenting agent, a moisturizing agent, an antiseborrheic or antiacne agent, an antibiotic, an antifungal agent, a hair regrowth promoter, a non-steroidal anti-inflammatory agent, a carotenoid, an anti-psoriatic agent, 5,8,11,14-eicosatetraynoic or 5,8,11-eicosatrynoic acid or ester or amide thereof, or combination thereof.

55. The pharmaceutical composition as defined by Claim 27, further comprising a taste- or flavor-enhancing agent, a preservative, a stabilizer, a moisture regulating agent, a pH regulating agent, an osmotic pressure modifying agent, an emulsifying agent, a UV-A or UV-B screening agent, an antioxidant, or combination thereof.

56. The cosmetic composition by Claim 49, further comprising a wetting agent, a depigmenting agent, a moisturizing agent, an antiseborrheic or antiacne agent, an antibiotic, an antifungal agent, a hair regrowth

promoter, a non-steroidal anti-inflammatory agent, a carotenoid, an anti-psoriatic agent, 5,8,11,14-eicosatetraynoic or 5,8,11-eicosatrynoic acid or ester or amide thereof, or combination thereof.

5           57. The cosmetic composition as defined by Claim  
49, further comprising a taste- or flavor-enhancing  
agent, a preservative, a stabilizer, a moisture  
regulating agent, a pH regulating agent, an osmotic  
pressure modifying agent, an emulsifying agent, a UV-A  
10 or UV-B screening agent, an antioxidant, or combination  
thereof.